Nabla
Nabla is a team of scientists and engineers focused on making drug development a design discipline by using generative drug design and patient-relevant testing to reduce trial-and-error.
Classification
Profile
Not yet available.
Funding
Funding details not yet available.
Signals
Transforms drug development into a design discipline using generative AI and patient-relevant testing to reduce trial-and-error and accelerate medicine delivery.
Pharmaceutical and biotechnology companies engaged in drug discovery and development.
Up-front research fees (typically $5-15 M per multi-year pharma collaboration) · Milestone payments tied to hit-rate, IND filing, or clinical-stage transitions · Royalties on commercialized therapeutics (5-12 % of net sales)
Direct business-development outreach to pharma R&D leadership (executive-level meetings, scientific workshops) · Strategic partnership announcements (press releases, industry conferences - e.g., BIO, JP Morgan Healthcare) · Thought-leadership content (peer-reviewed papers, blog posts, podcasts) that showcase platform performance
Information insufficient.
Scientific talent, engineering resources, and computational infrastructure for AI model development and validation.
Proprietary generative drug design technology, patient-relevant testing data, and a team of scientists and engineers.
Developing generative AI tools for drug design, conducting patient-relevant testing, and refining scientific standards.
Information insufficient.
Competes in AI-driven drug discovery by differentiating through patient-relevant testing and a culture prioritizing speed and scientific rigor over ego.
High failure rates and slow timelines in traditional drug development caused by excessive trial-and-error and lack of patient-relevant data.
- Diversify Revenue via Platform-as-a-Service (PaaS)
- Map current partner contracts to identify gaps where SaaS or data-marketplace clauses could be added
- Customer Segments ↔ Value Propositions - Pharma’s need for “undruggable” targets is directly satisfied by JAM’s ability to generate high-
- Validated Partnerships - Multi-year, high-value collaborations with three of the world’s top pharma companies (AstraZeneca, BMS, Takeda)
No investors recorded yet.